Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weight-loss supplement study

This article was originally published in The Tan Sheet

Executive Summary

An estimated 15.2% of adults have used dietary supplements for weight loss, and 73.8% of users have tried products containing a stimulant such as caffeine, ephedra or bitter orange, according to a study in the March issue of the Journal of the American Dietetic Association. Odds of use increased with BMI, but did not differ by ethnicity or education, Heidi Michaels Blank, Ph.D., Centers for Disease Control and Prevention, et al., find. Among those who had used weight-loss supplements within the last year, 16% reported using two products and the average reported duration was 3.7 months, the authors add. One in 10 users reported product-use duration of more than 12 months. The nationwide telephone survey of 11,000 adults was conducted from September through December 2002...

You may also be interested in...



Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial

Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies. 

Topics

UsernamePublicRestriction

Register

PS100284

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel